Please try another search
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Name | Age | Since | Title |
---|---|---|---|
Marianne D. Sadar | 62 | 2009 | Scientific Advisor |
Franklin M. Berger | 74 | 2015 | Independent Director |
Gary R. Sollis | 70 | 2012 | Independent Director |
Marella Thorell | 56 | 2019 | Independent Director |
Raymond Andersen | 76 | 2009 | Scientific Advisor |
Philip W. Kantoff | 68 | 2022 | Independent Director |
Richard M. Glickman | 65 | 2010 | Independent Chairman of the Board |
Scott Requadt | 55 | 2016 | Independent Director |
John Alexander Martin | 55 | 2019 | Independent Director |
Sanford S. Zweifach | 67 | 2019 | Independent Director |
Lauren Merendino | 48 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review